Pyrazolopyridine derivative acts as a novel cyclooxygenase inhibitor: antiplatelet effect in aged patients with ischemic stroke

  • J Am Geriatr Soc. 1994 Jun;42(6):639-42. doi: 10.1111/j.1532-5415.1994.tb06863.x.
K Satoh  1 ,  H Yoshida ,  T A Imaizumi ,  M Koyama ,  M Hiramoto ,  S Takamatsu
Affiliations
  • 1. Department of Pathological Physiology, Hirosaki University School of Medicine, Japan.
PMID: 8201150 DOI: 10.1111/j.1532-5415.1994.tb06863.x
Abstract

Objective: To examine the antiplatelet effect of a novel pyrazolopyridine derivative (KC-764) in geriatric patients with ischemic stroke.

Design: Randomized clinical trial of three graded dose levels.

Setting: A geriatric clinic attached to a nursing home.

Patients: Fifteen patients with a history of cerebral infarction with a mean age of 75 +/- 5 years (range, 65-83). Patients were divided into three groups and administered 10, 20, or 40 mg/day KC-764 for 8 weeks.

Measurements: Platelet aggregation induced by arachidonate, ADP, Collagen and platelet-activating factor. Plasma or serum levels of thromboxane B2 and 6-ketoprostaglandin F1 alpha.

Main results: Platelet aggregation was inhibited by KC-764 administration and returned to the control level after discontinuation. Although plasma thromboxane B2 levels were markedly decreased, plasma 6-ketoprostaglandin F1 alpha was not affected. However, the dose of 10 mg/day was not sufficient to maintain an effective plasma level of KC-764. There were no side effects or changes in laboratory findings.

Conclusions: We confirmed that KC-764 at a dose of 20 to 40 mg/day is an effective antiplatelet agent and a good candidate for a trial to see if it is feasible for long-term use for the prevention of ischemic stroke in high-risk patients.

Products